Suppr超能文献

一种新型 MMP-2 抑制剂 3-叠氮沃替西汀 A(3-azidoWA)通过调节细胞外 Par-4 来阻断癌细胞侵袭和血管生成。

A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4.

机构信息

Molecular Signal Transduction Laboratory, Cancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR), Jammu Tawi, India.

出版信息

PLoS One. 2012;7(9):e44039. doi: 10.1371/journal.pone.0044039. Epub 2012 Sep 4.

Abstract

BACKGROUND

Withaferin A, which is a naturally derived steroidal lactone, has been found to prevent angiogenesis and metastasis in diverse tumor models. It has also been recognized by different groups for prominent anti-carcinogenic roles. However, in spite of these studies on withanolides, their detailed anti-metastatic mechanism of action remained unknown. The current study has poised to address the machinery involved in invasion regulation by stable derivative of Withaferin A, 3-azido Withaferin A (3-azidoWA) in human cervical HeLa and prostate PC-3 cells.

METHODS AND PRINCIPAL FINDINGS

Sub-toxic concentration of 3-azidowithaferin A (3-azido WA) inhibited cancer cell motility and invasion in wound healing and Boyden chamber invasion by suppressing MMP-2 activity in gelatin zymography and its expression has proved to be a major obstacle in chemo-sensitivity. We have uncovered a novel mechanism of 3-azidoWA induced extracellular pro-apoptotic candidate tumor suppressor Par-4 protein stimulation in conditioned media and also noticed a concomitant marked reduction in pAkt and pERK signaling by immunoblot analysis. Furthermore, our zymography results suggest 3-azidoWA induced MMP-2 inhibition was mediated through secretory Par-4. The inhibition of apoptosis by 3-azidoWA could not restore MMP-2 gelatinase activity. In addition to this, our in vivo animal experiments data showed 3-azidoWA abrogated neovascularisation in dose dependent manner in mouse Matrigel plug assay.

CONCLUSION/SIGNIFICANCE: For this report, we found that 3-azidoWA suppressed motility and invasion of HeLa and PC-3 cells in MMP-2 dependent manner. Our in vitro result strongly suggests that sub-toxic doses of 3-azidoWA enhanced the secretion of extracellular Par-4 that abolished secretory MMP-2 expression and activity. Depletion of secretory Par-4 restored MMP-2 expression and invasion capability of HeLa and PC-3 cells. Further, our findings implied that 3-azidoWA attenuated internal phospho-ERK and phospho-Akt expression in a dose dependent manner might play a key role in inhibition of mouse angiogenesis by 3-azidoWA.

摘要

背景

Withaferin A 是一种天然衍生的甾体内酯,已被发现可防止多种肿瘤模型中的血管生成和转移。不同的研究小组也认识到它具有显著的抗癌作用。然而,尽管有这些关于 Withanolides 的研究,但它们的详细的抗转移作用机制仍然未知。本研究旨在研究稳定衍生物 3-叠氮 Withaferin A(3-azidoWA)在人宫颈 HeLa 和前列腺 PC-3 细胞中对侵袭调控的机制。

方法和主要发现

亚毒性浓度的 3-叠氮 Withaferin A(3-azidoWA)通过抑制明胶酶谱中的 MMP-2 活性及其表达,抑制了癌细胞的迁移和侵袭,在伤口愈合和 Boyden 室侵袭实验中,这被证明是化疗敏感性的主要障碍。我们发现了一种新的机制,即 3-azidoWA 诱导细胞外促凋亡候选肿瘤抑制因子 Par-4 蛋白在条件培养基中的刺激,并通过免疫印迹分析注意到伴随的 pAkt 和 pERK 信号的显著减少。此外,我们的酶谱结果表明,3-azidoWA 诱导的 MMP-2 抑制是通过分泌性 Par-4 介导的。3-azidoWA 对凋亡的抑制不能恢复 MMP-2 明胶酶活性。除此之外,我们的体内动物实验数据表明,3-azidoWA 以剂量依赖的方式在小鼠 Matrigel plugs 实验中阻断新生血管形成。

结论/意义:对于本报告,我们发现 3-azidoWA 以 MMP-2 依赖的方式抑制 HeLa 和 PC-3 细胞的迁移和侵袭。我们的体外结果强烈表明,亚毒性剂量的 3-azidoWA 增强了细胞外 Par-4 的分泌,从而消除了分泌性 MMP-2 的表达和活性。分泌性 Par-4 的耗竭恢复了 HeLa 和 PC-3 细胞的 MMP-2 表达和侵袭能力。此外,我们的研究结果表明,3-azidoWA 以剂量依赖的方式减弱了内部磷酸化 ERK 和磷酸化 Akt 的表达,这可能在 3-azidoWA 抑制小鼠血管生成中发挥关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83bc/3433490/dbdc158d56ee/pone.0044039.g001.jpg

相似文献

2
Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.
Eur J Pharmacol. 2019 Dec 1;864:172719. doi: 10.1016/j.ejphar.2019.172719. Epub 2019 Oct 3.
4

引用本文的文献

1
Iron Overloading Potentiates the Antitumor Activity of 5-Fluorouracil by Promoting Apoptosis and Ferroptosis in Colorectal Cancer Cells.
Cell Biochem Biophys. 2024 Dec;82(4):3763-3780. doi: 10.1007/s12013-024-01463-x. Epub 2024 Aug 4.
3
Evaluation of Antiproliferative Properties of CoMnZn-FeO Ferrite Nanoparticles in Colorectal Cancer Cells.
Pharmaceuticals (Basel). 2024 Mar 1;17(3):327. doi: 10.3390/ph17030327.
4
Tamarix articulata extract offers protection against toxicity induced by beauty products in Hs27 human skin fibroblasts.
PLoS One. 2023 Nov 16;18(11):e0287071. doi: 10.1371/journal.pone.0287071. eCollection 2023.
6
Medicinal Characteristics of L. in Colorectal Cancer Management.
Pharmaceuticals (Basel). 2023 Jun 22;16(7):915. doi: 10.3390/ph16070915.
7
The immunomodulatory role of (L.) dunal in inflammatory diseases.
Front Pharmacol. 2023 Feb 22;14:1084757. doi: 10.3389/fphar.2023.1084757. eCollection 2023.
8
Antioxidant, Wound Healing Potential and In Silico Assessment of Naringin, Eicosane and Octacosane.
Molecules. 2023 Jan 20;28(3):1043. doi: 10.3390/molecules28031043.
10
: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics.
Pharmaceutics. 2022 Mar 10;14(3):611. doi: 10.3390/pharmaceutics14030611.

本文引用的文献

1
Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential.
Steroids. 2011 Sep-Oct;76(10-11):1213-22. doi: 10.1016/j.steroids.2011.05.012. Epub 2011 Jun 12.
4
Matrix metalloproteinases: regulators of the tumor microenvironment.
Cell. 2010 Apr 2;141(1):52-67. doi: 10.1016/j.cell.2010.03.015.
5
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
Cancer Biol Ther. 2009 Dec;8(24):2371-3. doi: 10.4161/cbt.8.24.10353. Epub 2009 Dec 19.
6
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.
Mol Cancer Res. 2009 Nov;7(11):1803-12. doi: 10.1158/1541-7786.MCR-08-0336. Epub 2009 Nov 10.
7
The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis.
Cell. 2009 Jul 23;138(2):377-88. doi: 10.1016/j.cell.2009.05.022.
8
Restoration of stress-induced altered T cell function and corresponding cytokines patterns by Withanolide A.
Int Immunopharmacol. 2009 Sep;9(10):1137-44. doi: 10.1016/j.intimp.2009.05.011. Epub 2009 Jun 12.
10
To kill a tumor cell: the potential of proapoptotic receptor agonists.
J Clin Invest. 2008 Jun;118(6):1979-90. doi: 10.1172/JCI34359.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验